News

Press Releases and Media
Press Releases
November 22, 2021
Attralus to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
Press Releases
November 4, 2021
Attralus to Present New Data at 2021 American Society of Hematology Annual Meeting
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
Press Releases
September 8, 2021
Attralus Closes $116 Million Series B Financing
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
In the News
August 2, 2021
Meet the 24 biotech startups that top VCs say are poised to take off in the next 12 months
Business Insider
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
In the News
July 30, 2021
BioSpace Movers & Shakers, July 30, 2021
BioSpace
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
Press Releases
July 28, 2021
Attralus Appoints Jake Bauer to Board of Directors
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
Press Releases
June 15, 2021
Attralus Announces Presentation of Clinical Data on AT-01, a Novel Diagnostic for Systemic Amyloidosis, at the 2021 Society of Nuclear Molecular Imaging Meeting
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
Posters & Publications
June 15, 2021
Synthesis of 99m Tc-labeled Peptide p5+14 for Detection of Cardiac Amyloidosis – Preclinical Studies in a Mouse Model
Poster Number 3007
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
Posters & Publications
June 15, 2021
Presentation: Multi-amyloid Reactivity of the Peptide Imaging Agent 124I-p5+14 (AT-01) in Patients with Amyloidosis
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
Posters & Publications
June 15, 2021
Clinical Utility of PET/CT Imaging with Peptide Imaging Agent 124I-p5+14 (AT-01) in Patients with Systemic Amyloidosis
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
Posters & Publications
June 15, 2021
Quantification of Peptide 124I-p5+14 (AT-01) Uptake in Patients with Systemic Amyloidosis
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
In the News
May 24, 2021
AT-01 Can Detect Amyloid Deposits in Heart of Asymptomatic Patients
FAP News Today
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
Press Releases
May 17, 2021
Attralus Announces Presentation of Clinical Data on AT-01, a Novel, Potential First-in-Class Diagnostic for Systemic Amyloidosis at the 2021 American College of Cardiology Annual Meeting
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
Posters & Publications
May 17, 2021
Detection and Differentiation of Cardiac Amyloidosis Using [124]I-P5+14 PET/CT Imaging and the Correlation with Clinical Biomarkers
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
Press Releases
May 10, 2021
Attralus Appoints Mark Timney as CEO and Expands Leadership Team with New Executives
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
In the News
January 19, 2021
Imaging Agent Can Help Differentiate Between Amyloidosis Types
FAP News Today
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
Press Releases
December 6, 2020
Attralus Presents Clinical Data from Novel, Potential First-in-Class Diagnostic AT-01 for Systemic Amyloidosis at Virtual ASH 2020
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
Press Releases
November 5, 2020
Attralus to Present Clinical Data at Upcoming Virtual ASH 2020
prnewswire.com
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
In the News
October 1, 2020
Reversing disease pathology in amyloidosis: Attralus launches with $25m Series A
Pharmaceutical Technology
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
Press Releases
September 14, 2020
Attralus Launches with $25 Million Series A Financing from venBio Partners to Transform Treatment for Patients with Systemic Amyloidosis
prnewswire.com
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
Press Releases
September 14, 2020
Attralus Presents Preclinical and Clinical Data at 17th International Symposium on Amyloidosis
prnewswire.com
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
In the News
September 14, 2020
Attralus Eyes Further Work on Therapeutic Candidates with New Funding
www.biospace.com
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
In the News
September 14, 2020
Attralus Raises $25 Million to Transform Treatment for Patients with Systemic Amyloidosis
globalgenes.org
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
In the News
September 14, 2020
The Crunchbase News Briefing: Mon., Sept. 14
news.crunchbase.com
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
In the News
September 14, 2020
Attralus Raises $25M in Series A Financing
finsmes.com
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
In the News
September 14, 2020
Attralus Secures $25M Series A to Diagnose and Treat Amyloidosis
timmermanreport.com
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
In the News
September 14, 2020
Attralus debuts with $25M series A to tackle systemic amyloidosis
biocentury.com
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
Press Releases
December 8, 2019
Aurora Bio, Inc Announces Clinical Data on Lead Program
businesswire.com
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free
Read More
close button😔

Attralus Job

AD/Director, Program Management
Attralus, Inc., (formerly Aurora Bio) is a VC funded privately held development stage biotechnology company focused on improving the lives of systemic amyloidosis patients, through the development of novel diagnostics and therapeutics...
Read More

AD/Director, Program Management

<< Back

Overview

Attralus, Inc., (formerly Aurora Bio) is a VC funded privately held development stage biotechnology company focused on improving the lives of systemic amyloidosis patients, through the development of novel diagnostics and therapeutics. We are developing pan-amyloid targeting agents that facilitate diagnosis, and the development of novel immunotherapies designed to clear amyloid fibrils in patients with systemic amyloid diseases. We aim to improve the diagnosis and treatment of systemic amyloid diseases, such as light chain (AL), transthyretin (ATTR), and LECT2 amyloidosis, to increase patient survival and quality of life.

Attralus’ technology has broad applications and the potential to address up to 30 systemic amyloid based diseases.  Attralus has a diagnostic imaging agent currently in a ph 1/2 trial, positioned to potentially be the first approved diagnostic specifically for amyloidosis. The company also has 2 novel therapeutic fusion proteins, directed at amyloid removal, that are in pre-clinical development

Headquartered in South San Francisco and founded in 2019, Attralus has recently completed a Series A funding with VenBio to carry forward its mission to improve the lives of systemic amyloidosis patients

Description

The AD/Director, Program Management will be responsible for providing both strategic and hands-on program and project management expertise. Initially reporting directly to the CEO, the AD/Director will be responsible for creating the program plan and budget and providing daily coordination and tracking of critical activities, assuring all milestones and deliverables are met. The Director will be responsible for developing the program management processes and procedures for the company, determining appropriate software and other tools, structuring regular meetings and communication within the company and with external collaborators.

Responsibilities

Collaborate with the management team to provide project management leadership and execution activities within the company and between external partners and Attralus teams.

Develop and execute integrated cross-functional project plans with established goals, milestones, timelines and budget, with a key focus on bringing pre-clinical therapeutic programs into early clinical development

Conduct and direct day-to-day program activities to meet milestones; monitoring critical path activities to ensure delivery of program objectives.

Drive planning for key drug development milestones.

Maintain effective communication with the management team through oral and written correspondence and ensure adequate documentation of each communication. 

Always use/model/maintain/promote best practices in Program Management, including the use of agendas, minutes, dashboards, maintain document repository, establish and implement templates, tools, and processes to drive efficiency, alignment, communication, and effective planning.

Create and maintain easily accessible, high level program documents in electronic format. 

Recommend, manage and train on necessary software and tools.

Identify, develop and/or maintain an appropriate electronic platform (SharePoint, Shared Folders, etc.) for reporting/archiving/documentation of relevant program information, records, etc. 

Conduct risk management, contingency and scenario planning using appropriate program management tools.

Identify program issues or resource gaps and facilitate resolution.

Communicate program information and support development of program presentations to senior leadership, board members, investors and other key stakeholders as appropriate.

Contribute to budgetary planning at the program level.

Facilitate adherence to Aurora’s governance processes; work with key stakeholders to prepare for those interactions; lead/support as appropriate. Ensure implementation of governance decisions.

Qualifications

Minimum of a BA/BS in a scientific disciplined is required, Advance degree preferred

7+ years of program management or equivalent experience in a pharmaceutical or biotechnology organization.

Experience with research/pre-clinical and early clinical development project planning required. PM Certification is a plus.

Rare disease experience a strong plus (not required).

Desire and ability to work in a start-up, fast paced organization where you will wear many hats.

Must have excellent verbal and written communication skills as well as exceptional organizational capability.

Ability to drive program plans and timelines (across multiple functional areas) is essential.  Proven success in goal setting, prioritization and time management is required.

Understanding of FDA and/or EMA quality and regulatory processes. Prior experience with regulatory filings is desirable. 

Experience working with external partners is desirable.

Ability to work independently in decision-making and resolution of program obstacles and conflicts.

Familiarity with developing budgets and forecasting is desirable.

Ability to function autonomously, with an appreciation of detail while being cognizant of “the big picture.”

Have a patient-first mindset. All decisions made with patients in mind.

Proficiency with Microsoft Word, Excel, PowerPoint, and Project is required.

Benefits/Equal Opportunity Employer

Attralus, Inc. offers both comprehensive benefits and Paid Time Off (PTO) plans for employees, which begin on the first day of employment.

Attralus, Inc. is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.

our apologies

TABLET & MOBILE EXPERIENCES
ARE STILL UNDER CONSTRUCTION

Please view on a desktop or laptop computer.